Amneal Pharmaceuticals, Inc. - Class A (AMRX)
AMRX moved a median of -0.08% 30 minutes after news, and -0.16% by the close. How AMRX actually reacts to news — the realized, point-in-time move the market made, measured across 377 labeled events over the last three years with zero look-ahead.
AMRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.06% | 45% | 374 |
| 30-min | -0.08% | 46% | 374 |
| 60-min | -0.16% | 42% | 374 |
| to close | -0.16% | 42% | 372 |
| Middle 50% of AMRX reactions | -1.03% to +0.58% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 377 |
Half of all Amneal Pharmaceuticals, Inc. - Class A news events land between -1.03% and +0.58% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AMRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | +0.12% | 53% | -1.99% |
| Coverage initiations | 15 | +0.25% | 67% | +0.23% |
| Rating reiterations | 25 | 0.00% | 48% | -0.12% |
| Price-target raises | 12 | +0.09% | 50% | -0.24% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how AMRX ranks against every other measured name →
That’s how AMRX usually reacts — get an email when it moves on news →Email me when AMRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AMRX's baseline. Nothing else.
Recent AMRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Amneal to Report Third Quarter 2026 Results on November 3, 2026 | Press release | GlobeNewswire | -1.09% | +0.00% | |
| Amneal Announces FDA Approval and Launch of Lanreotide Injection | Press release | GlobeNewswire | -0.18% | +6.67% | |
| Form S-3ASR Amneal Pharmaceuticals, | SEC filing · Form S-3ASR | SEC EDGAR | +0.11% | -0.74% | |
| STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm | Press release | Business Wire | -0.30% | -2.16% | |
| Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader | Press release | GlobeNewswire | +0.53% | — | |
| Form 10-Q Amneal Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.05% | -0.06% | |
| Form 8-K Amneal Pharmaceuticals, For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -2.05% | -2.79% | |
| Form 8-K Amneal Pharmaceuticals, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +1.07% | +2.22% | |
| Amneal Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.06% | +1.54% | |
| Form 8-K Amneal Pharmaceuticals, For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | +1.54% | |
| Form DEFA14A Amneal Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.06% | +1.54% | |
| Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm | Press release | Business Wire | -0.14% | +0.67% | |
| Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations | Press release | GlobeNewswire | +2.13% | -0.17% | |
| Amneal to Report Second Quarter 2026 Results on July 30, 2026 | Press release | GlobeNewswire | -0.65% | +0.59% | |
| Form DEFM14A Amneal Pharmaceuticals, | SEC filing · Form DEFM14A | SEC EDGAR | -0.12% | +1.05% | |
| Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations | Press release | GlobeNewswire | -0.12% | +1.05% | |
| Form PREM14A Amneal Pharmaceuticals, For: Jun 18 | SEC filing · Form PREM14A | SEC EDGAR | +0.71% | -0.62% | |
| Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals | Press release | PR Newswire | +0.98% | +0.13% | |
| Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease | Press release | GlobeNewswire | +1.18% | +1.25% | |
| Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution | Press release | GlobeNewswire | +1.46% | +4.00% | |
| Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026 | Press release | GlobeNewswire | -1.30% | -1.23% | |
| Amneal Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.73% | -4.21% | |
| Form 10-Q Amneal Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.73% | -4.21% | |
| Form 8-K Amneal Pharmaceuticals, For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | -4.21% | |
| Form 8-K Amneal Pharmaceuticals, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | -4.21% | |
| Form DEFA14A Amneal Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -0.32% | -0.48% | |
| Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance | Press release | GlobeNewswire | +2.64% | -3.39% | |
| Form 8-K Amneal Pharmaceuticals, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +2.64% | -3.39% | |
| Form DEFA14A Amneal Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +2.64% | -3.39% | |
| Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader | Press release | Business Wire | +2.64% | -3.39% | |
| Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY® | Press release | GlobeNewswire | -0.97% | -4.60% | |
| Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. | Press release | GlobeNewswire | +1.01% | +2.26% | |
| Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% | Press release | GlobeNewswire | +0.16% | +1.59% | |
| Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month | Press release | GlobeNewswire | +0.49% | +1.40% | |
| Amneal to Report First Quarter 2026 Results on May 1, 2026 | Press release | GlobeNewswire | -0.79% | -0.16% | |
| Form DEF 14A Amneal Pharmaceuticals, For: May 06 | SEC filing · Form DEF | SEC EDGAR | +0.17% | -0.66% | |
| Form DEFA14A Amneal Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.17% | -0.66% | |
| Amneal to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | -0.19% | +1.22% | |
| Amneal Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +1.69% | -2.95% | |
| Form 10-K Amneal Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.67% | -0.72% | |
| Form 8-K Amneal Pharmaceuticals, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | -2.95% | |
| Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market | Press release | PR Newswire | -0.13% | -0.80% | |
| Form 8-K Amneal Pharmaceuticals, For: Feb 02 | SEC filing · Form 8-K | SEC EDGAR | +1.27% | +0.71% | |
| Amneal Pharmaceuticals Added to S&P SmallCap 600® Index | Press release | GlobeNewswire | +1.61% | +0.86% | |
| Form 8-K Amneal Pharmaceuticals, For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | +1.61% | +0.86% | |
| Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 | Press release | GlobeNewswire | +2.14% | +2.14% | |
| Form 8-K Amneal Pharmaceuticals, For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -0.69% | +0.15% | |
| KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease | Press release | Business Wire | +0.19% | -0.35% | |
| Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® | Press release | GlobeNewswire | +0.39% | +0.39% | |
| mAbxience and Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® | Press release | PR Newswire | +0.39% | +0.39% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AMRX section they belong to.
Where else AMRX is measured.
AMRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| REPRO MED SYSTEMS INC (REPR) | 378 | 0.00% | 26% |
| Akebia Therapeutics, Inc. (AKBA) | 377 | 0.00% | 49% |
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
| Solid Biosciences Inc. (SLDB) | 375 | -0.17% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Amneal Pharmaceuticals, Inc. - Class A's median reaction calculated?
Every labeled AMRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 377 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of AMRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AMRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.